Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. (NASDAQ: KIDS) is an orthopedic medical device company focused exclusively on pediatric orthopedics, and its news flow reflects this specialization. Company announcements frequently cover revenue updates, financial guidance, and quarterly earnings, where OrthoPediatrics discusses performance across its trauma and deformity, scoliosis, and specialty bracing (OPSB) product lines, as well as metrics such as the number of children treated with its systems.
Readers following KIDS news can expect regular updates on financial results and outlook, including preliminary unaudited revenue releases, full quarterly earnings reports, and adjustments to annual guidance. These releases often highlight contributions from specific product categories, trends in domestic and international revenue, and management’s commentary on operational initiatives such as restructuring efforts and cost management.
OrthoPediatrics also issues news on product development and regulatory milestones. Recent examples include FDA approval of the 3P Pediatric Plating Platform Small-Mini System, additional FDA clearances within a single year, and EUMDR certification for spine, trauma, and deformity implants and instruments. The company reports on first clinical procedures with new systems, such as the VerteGlide Spinal Growth Guidance System for early onset scoliosis, and on portfolio expansions like new PediHip bracing products within OPSB.
In addition, KIDS news includes strategic and corporate updates, such as distribution partnerships (for example, with MY01 for Continuous Perfusion Sensing Technology), expansion of OPSB clinics and territories, participation in healthcare and investor conferences, and changes to the board of directors. Investors and observers who monitor this news stream gain insight into how OrthoPediatrics is evolving its pediatric orthopedic platform, broadening its product offering, and engaging with clinicians and the capital markets.
OrthoPediatrics Corp. (KIDS) announced the launch of its RESPONSE 5.5/6.0 Cannulated Screw System, enhancing its RESPONSE™ Scoliosis portfolio. This marks the company's 47th surgical system, reinforcing its commitment to pediatric orthopedic innovation. The system features instruments and implants designed to improve screw placement accuracy and efficiency in surgeries. Early feedback from surgeons has been overwhelmingly positive, highlighting the system's effectiveness for the S1AI screw placement technique. The new product reflects OrthoPediatrics' dedication to advancing pediatric orthopedic solutions and its global reach in serving over 70 countries.
OrthoPediatrics Corp. (NASDAQ: KIDS) announced the upcoming release of its first quarter 2023 financial results on May 1, 2023, after market close. A conference call will be held on May 2, 2023, at 8:00 a.m. ET to discuss these results. The company, founded in 2006, specializes in pediatric orthopedics and currently offers 47 surgical systems targeting trauma, deformity, scoliosis, and sports medicine. OrthoPediatrics operates globally, distributing its products in the U.S. and over 70 additional countries. Investors can access the conference call via a live and archived webcast on the company's website.
OrthoPediatrics Corp. (Nasdaq: KIDS) will have its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 8:45 am ET. This event highlights the company's dedication to pediatric orthopedics, having developed the most comprehensive product offerings in this field. Founded in 2006, OrthoPediatrics markets 47 surgical systems across trauma, scoliosis, and sports medicine, serving the U.S. and over 70 countries globally. An audio webcast will be available at their investor relations site, with a replay following the event.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its sponsorship at the European Pediatric Orthopaedic Society (EPOS) annual meeting in Krakow, Poland. The company showcased its commitment to pediatric orthopedics by hosting an exhibit and a surgeon luncheon focused on Osteogenesis Imperfecta, featuring insights from leading surgeons. This event fosters collaboration among orthopedic surgeons across Europe, enhancing educational opportunities in the field. Currently, OrthoPediatrics offers 47 surgical systems covering trauma, scoliosis, and sports medicine, distributing its products in the U.S. and over 70 countries worldwide.
OrthoPediatrics Corp. (Nasdaq: KIDS) has been recognized as one of the 2023 Best Places to Work in Indiana, marking the 7th time the company has received this honor. Due to the company's growth, it now qualifies in the 'Large Employer' category. CEO David Bailey expressed pride in the achievement, emphasizing the importance of employee feedback in fostering a positive workplace culture. The awards ceremony will occur on May 10, 2023, and the final rankings will be published in the Indiana Chamber’s BizVoice® magazine. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering 46 surgical systems worldwide.
OrthoPediatrics Corp. (KIDS) reported a 25% increase in fourth quarter 2022 revenue, reaching $31.0 million, and a record $122.3 million for the full year 2022, also a 25% rise from 2021. The company helped nearly 17,000 children in Q4 and approximately 70,000 children throughout the year. Domestic and international revenues rose by 19% and 47% respectively for the year. Adjusted EBITDA improved to a positive $0.2 million. For 2023, the company expects revenue to be between $146 million to $149 million, anticipating 20% to 22% growth compared to 2022.
OrthoPediatrics Corp. (NASDAQ: KIDS) announced it will release its Q4 and full year 2022 financial results on February 28, 2023, after market close. A conference call to discuss these results is scheduled for March 1, 2023, at 8:00 a.m. ET. The call can be accessed through a live and archived webcast on the company's website. OrthoPediatrics specializes in pediatric orthopedics, offering 46 surgical systems for trauma, scoliosis, and sports medicine, distributing its products in the U.S. and over 70 countries globally.
Summary not available.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced preliminary unaudited net revenue for Q4 2022 at $31.0 million, a 25% increase from $24.8 million in Q4 2021. Full year 2022 net revenue is projected at $122.3 million, up 25% from $98.0 million in 2021. Domestic revenue grew 19% and international revenue increased by 47%. For 2023, the company forecasts net revenue between $146.0 million and $149.0 million, reflecting a growth of 20% to 22%. The report highlighted challenges due to surgery schedule disruptions in children's hospitals due to viral infections but emphasized a strong strategic position.
OrthoPediatrics Corp. (Nasdaq: KIDS) has launched a direct sales organization in Germany, commencing operations on January 1, 2023. This marks its first direct international presence, reflecting a commitment to enhance pediatric orthopedics globally. The new entity, OrthoPediatrics GmbH, aims to better address the unique needs of the German pediatric community, one of Europe’s largest orthopedic markets. The company will continue partnerships with local organizations to support pediatric orthopedic education. OrthoPediatrics offers a comprehensive range of products targeting trauma, deformity correction, and spinal issues.